Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 5 of 65 · 3078 articles
If validated, blood antibody patterns could allow earlier identification of people at risk for Crohn’s disease or ulcerative colitis — potentially before bowel damage occurs — opening opportunities for earlier monitoring...
Researchers are exploring targeted oral delivery and immune‑modulating strategies for colitis in older hosts; this study suggests a nanoparticle approach can alter T cell aging signs and the gut microbiome in mice, which...
The study identifies a molecular mechanism that links immune cell metabolism (Th17 glycolysis) with intestinal inflammation and colitis-associated cancer in experimental models. That pathway could eventually yield new...
Researchers are exploring targeted oral delivery methods to improve treatment of colitis in older individuals. If translatable, a colon-targeted nanogel that boosts regulatory T cells and favorably shifts the microbiome...
Blood platelet indices (PLR, MPV) are simple blood-test measures that may help detect IBD activity and show changes with biologic treatment. If validated, they could offer an inexpensive, noninvasive way to supplement...
A simple, low-cost fecal blood assay for mice can speed and lower the cost of preclinical studies of colorectal cancer and GI diseases. For IBD/Crohn’s research, it offers a way to monitor intestinal bleeding and link it...
The study suggests people with IBD consumed more dietary emulsifiers than healthy controls and found initial links between higher UPF/emulsifier intake and worse IBD-related events, which could be important if diet...
Nutritional disorders in IBD (underweight/malnutrition, overweight/obesity, and muscle loss/sarcopenia) are common and affect treatment tolerance, recovery, and quality of life. Knowing how frequent these problems are...
The study identifies a specific fibroblast–macrophage interaction driven by collagen IV that may explain how chronic IBD inflammation progresses to fibrosis and cancer, highlighting possible new molecular targets to...
Fibrostenotic strictures are a major unmet need in Crohn’s disease because anti-inflammatory drugs often cannot reverse established scarring; IL-11 is a biologically plausible target that might selectively affect...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Infliximab, and Anti-TNF. The original article is from Current Gastroenterology...
Fatigue is a common, disabling issue in Crohn’s disease with unclear biology. This study suggests measurable brain-structure differences correlate with fatigue severity and may modify how disease activity influences...
The article discusses peptide compounds that people with Crohn’s and other IBDs are exploring for gut barrier support and inflammation — a topic many patients consider when seeking adjunctive or experimental approaches.
If true, the findings suggest that everyday chemicals (bisphenols) might influence immune pathways relevant to IBD and that RORC could be a molecular link — potentially relevant for researchers studying environmental...
IUS with the IBUS‑SAS score may offer a reliable, noninvasive way to monitor Crohn’s disease activity that correlates with clinical scores and biomarkers and aligns well with CT/MRI for most findings.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Probiotics and Antimicrobial Proteins.
Peptides are being studied for targeted ways to reduce gut inflammation and help restore the intestinal lining — potential relevance for future Crohn’s/IBD therapies.
Cure8 found this source from intellectia.ai, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.
Longer-term and real-world data help patients and clinicians understand how well risankizumab and upadacitinib maintain clinical and endoscopic improvement over years of treatment, and early data on an investigational...
Preclinical evidence that a natural compound (Fraxin) can reduce epithelial necrosis and inflammation in UC models points to a potential new target (P2Y14R/cAMP/PKA/CREB) for future drug research and possibly novel...
FMT is shown here to be an effective option for treating recurrent C. difficile infection, including for patients who also have IBD — a group often vulnerable to recurrent infections and complications.
Researchers and clinicians want biomarkers that predict outcome or tailor treatment. This study suggests a mucosal gene-expression score is prognostic and declines in responders, but it does not yet show the score...
MRE is a widely used, noninvasive test that increasingly helps characterize disease phenotype and prognosis in Crohn's disease and IBD, which can affect monitoring and treatment planning.
The study directly compares fatigue levels across several chronic conditions using the same validated tools, offering context for how fatigue in IBD compares to other illnesses. That context can help patients and...
Patients and clinicians use the term "disease burden" to describe more than inflammation alone; it affects symptoms, daily function, mental health, and healthcare use. A clearer, integrated way to measure burden could...
Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Mirikizumab, IL-23 inhibitor, and Research and clinical trials. Open the original article for the full details.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Archives of medical science : AMS.
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Frontiers in medicine.
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Frontiers in immunology.
The study identifies acid ceramidase in myeloid cells as a regulator of sphingolipid metabolites and immune cell recruitment in a mouse model of chronic colitis, pointing to a possible new therapeutic target for IBD.
For people hospitalized with acute severe UC, the findings suggest that measuring early infliximab pharmacokinetics could help personalize rescue therapy and potentially reduce colectomy risk by identifying who may need...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Translational...
Understanding microbiota–neuroimmune interactions could explain why symptoms like urgency and pain persist in some people with UC and may point to new treatment strategies that go beyond conventional anti-inflammatory...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Translational...
The findings suggest that tissue-based immune profiling may better identify biologically distinct subgroups in ulcerative colitis than blood tests, which could affect research on personalized treatment or trial...
If replicated and confirmed, the genetic evidence that shorter telomeres increase risk of fibrotic lung disease (IPF) helps clarify that telomere length itself — not just telomerase-pathway genes — may be relevant to...
This study suggests a plant extract (Macleaya cordata) and its component sanguinarine reduced inflammation and improved colitis signs in mice by changing gut bacteria and macrophage activation — mechanisms relevant to...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Mirikizumab, and IL-23 inhibitor. The original article is from JMA journal.
Purinergic signaling connects nerves, immune cells, epithelium, and microbiota in the gut — pathways that can influence inflammation, motility, and pain relevant to IBD. Understanding these mechanisms could point to new...
This study aims to show how mirikizumab and other biologics perform in everyday community practice — information that can help clinicians and patients understand real-world treatment durability, symptom control, and...
This study aims to measure how much time people with ulcerative colitis spend with objectively uncontrolled inflammation and to compare real-world outcomes of different initial advanced-therapy choices and...
A Phase 3 study is testing whether upadacitinib is safe and effective for children with moderate-to-severe Crohn's disease who have not responded to or cannot take other therapies. Positive results could expand treatment...
The study links an experimental treatment (dexpanthenol) to reduced inflammatory cytokines and improved anxiety-like behaviors in a rat colitis model, which is relevant to research on inflammation-driven gut–brain...
If reliable, blood biomarkers that track IBD activity could help noninvasively follow children with Crohn’s disease or ulcerative colitis. This study suggests MMP-9 and TIMP-1 change with disease course but did not show...
The work suggests new molecular readouts (fecal metaproteomics and lysine crotonylation) that could help explain why some people with ulcerative colitis respond to FMT while others do not, potentially guiding future...
A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.
The trial tests a naturally derived oral supplement (WPMDE2) in patients with ulcerative colitis, measuring symptoms, inflammatory markers, and quality of life—outcomes that matter to people living with IBD. Early-phase...
A registry focused on "difficult-to-treat" IBD aims to describe how often and why patients become treatment-refractory, how their disease and treatments evolve over time, and which outcomes (hospitalization, surgery,...
